Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 590 Madison Avenue, 21St Floor NEW YORK NY 10022 |
Tel: | N/A |
Website: | https://hoththerapeutics.com |
IR: | See website |
Key People | ||
Robb Knie President, Chief Executive Officer, Director | David S. Briones Chief Financial Officer |
Business Overview |
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus. |
Financial Overview |
For the fiscal year ended 31 December 2023, Hoth Therapeutics Inc revenues was not reported. Net loss decreased 31% to $7.8M. Lower net loss reflects Losses on marketable securities decrease from $387K (expense) to $0K, Change in fair value of investments in j increase from $377K (expense) to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$9.50 to -$2.30. |
Employees: | 2 as of Mar 26, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$7.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.85M as of Dec 31, 2023 |
Free cash flow (TTM): | -$8.45M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,888,804 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |